Back to Search
Start Over
[New targeted therapies in hormone-refractory prostate cancer].
- Source :
-
Bulletin du cancer [Bull Cancer] 2007 Jul; Vol. 94 (7 Suppl), pp. F62-8. - Publication Year :
- 2007
-
Abstract
- Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. Effective treatments have not existed for prostate cancer progressing after androgen deprivation therapy until recently. Docetaxel based chemotherapy has demonstrated to extend patient survival in two large randomized studies. These studies have provided the impetus to combine docetaxel with novel biologic drugs to further consolidate the gains in long-term outcome. With the arrival of new therapies such as epothilone analogues, small molecule receptor tyrosine kinase inhibitors, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenics drugs and endothelin receptor antagonists, the future of prostate cancer therapy appears promising.
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal therapeutic use
Boronic Acids therapeutic use
Bortezomib
Calcitriol therapeutic use
Cancer Vaccines therapeutic use
Diphosphonates therapeutic use
Docetaxel
Endothelin-1 antagonists & inhibitors
Epothilones therapeutic use
Humans
Male
Oligonucleotides, Antisense therapeutic use
Organoplatinum Compounds therapeutic use
Protease Inhibitors therapeutic use
Protein Kinase Inhibitors therapeutic use
Pyrazines therapeutic use
Taxoids therapeutic use
Antineoplastic Agents therapeutic use
Drug Resistance, Neoplasm
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 94
- Issue :
- 7 Suppl
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 17845995